## Supplementary material

### Regression model for LV-trait associations

#### Supplementary Note 1: mean type I error rates and calibration of LV-based regression model {#sm:reg:null_sim}

We assessed our GLS model type I error rates (proportion of $p$-values below 0.05) and calibration using a null model of random traits and genotype data from 1000 Genomes Phase III.
We selected 312 individuals with European ancestry, and then analyzed 1,000 traits drawn from a standard normal distribution $\mathcal{N}(0,1)$.
We ran all the standard procedures for the TWAS approaches (S-PrediXcan and S-MultiXcan), including:
1) a standard GWAS using linear regression under an additive genetic model,
2) different GWAS processing steps, including harmonization and imputation procedures as defined in [@doi:10.1002/gepi.22346],
3) S-PrediXcan and S-MultiXcan analyses.
Below we provide details for each of these steps.

**Step 1 - GWAS**. We performed standard QC procedures such as
filtering out variants with missing call rates eexceeding 0.01, MAF below 1% or MAC below 20, and HWE below 1e-6,
and removing samples with high sex-discrepancy and high-relatedness (first and second degree).
We included sex and the top 20 principal components as covariates, performing the association test on 5,923,554 variants across all 1,000 random phenotypes.

**Step 2 - GWAS processing**. These steps include harmonization of GWAS and imputation of $z$-scores, which are part of the TWAS pipeline and are needed in order to ensure an acceptable overlap with SNPs in prediction models.
The scripts to run these steps are available in [@url:https://github.com/hakyimlab/summary-gwas-imputation].
These procedures were run for all 1,000 random phenotypes and generated a total number of 8,325,729 variants, including those with original and imputed $z$-scores.
`maybe show some manhattan plot?`{.red}

**Step 3 - TWAS**. We processed the imputed GWAS with S-PrediXcan using the MASHR prediction models on 49 tissues from GTEx v8.
Then, S-MultiXcan was ran using the GWAS and S-PrediXcan outputs to generate gene-trait association $p$-values.
`maybe show some manhattan plot?`{.red}

Finally, we ran our GLS model (Equation (@eq:reg:model)) to compute an association between each of the 987 LVs in MultiPLIER and the 1,000 S-MultiXcan results on random phenotypes.
For this, we built a gene correlation matrix specifically for this cohort (see [Methods](#sec:methods:reg)).
Then, we compared the GLS results with an equivalent, baseline ordinarly least squares (OLS) model assuming independence between genes.
Figure @fig:reg:nulls:qqplots compares the distribution of $p$-values of the OLS and GLS models.
The GLS model has a slightly smaller mean type I error rate (0.0558, SD=0.0127) than the baseline OLS model (0.0584, SD=0.0140), and $p$-values follow more closely the expected uniform distribution.
Importantly, the GLS model is able to correct for LVs with adjacent and highly correlated genes at the top such as LV234 (Figure @fig:reg:nulls:qqplot:lv234), LV847 (Figure @fig:reg:nulls:qqplot:lv847), LV45 (Figure @fig:reg:nulls:qqplot:lv45), or LV800 (Figure @fig:reg:nulls:qqplot:lv800), among others.
In contrast and as expected, the OLS model has higher mean type I errors and smaller-than-expected $p$-values in all these cases.

We also detected other LVs with higher-than-expected mean type I errors for both the GLS and OLS models, although they don't have a relatively large number of adjacent genes at the top.
One example is LV914, shown in Figure @fig:reg:nulls:qqplot:lv914.
Inflation in these LVs might be explained by inaccuracies in correlation estimates between the individual-level MultiXcan model and its summary-based version (see Methods).
Therefore, we flagged those with a type I error rate larger than 0.07 (127 LVs) and excluded them from our main analyses.

![
**QQ-plots for OLS (baseline) and GLS (PhenoPLIER) models on random phenotypes.**
](images/gls/null_sims/models_qqplots.png "QQ-plots for OLS and GLS models"){#fig:reg:nulls:qqplots width="80%"}

![
**QQ-plots for LV234 on random phenotypes.**
Among the top 1% of genes in this LV, 17 are located in band 6p22.2, 5 in 6p22.1 and 3 in 7q11.23.
](images/gls/null_sims/models_lv234.png "QQ-plots for LV234"){#fig:reg:nulls:qqplot:lv234 width="80%"}

![
**QQ-plots for LV847 on random phenotypes.**
Among the top 1% of genes in this LV, 15 are located in band 6p22.2, 5 in 6p22.1 and 2 in 15q26.1.
](images/gls/null_sims/models_lv847.png "QQ-plots for LV847"){#fig:reg:nulls:qqplot:lv847 width="80%"}

![
**QQ-plots for LV45 on random phenotypes.**
Among the top 1% of genes in this LV, 12 are located in band 6p22.2, 6 in 6p22.1 and 3 in 1q23.3.
](images/gls/null_sims/models_lv45.png "QQ-plots for LV45"){#fig:reg:nulls:qqplot:lv45 width="80%"}

![
**QQ-plots for LV800 on random phenotypes.**
Among the top 1% of genes in this LV, 16 are located in band 19q13.43, 9 in 19p13.2 and 9 in 19q13.31.
](images/gls/null_sims/models_lv800.png "QQ-plots for LV800"){#fig:reg:nulls:qqplot:lv800 width="80%"}

![
**QQ-plots for LV914 on random phenotypes.**
Among the top 1% of genes in this LV, 2 are located in band 13q13.3, 2 in 7p15.2 and 2 in 19q13.2.
](images/gls/null_sims/models_lv914.png "QQ-plots for LV914"){#fig:reg:nulls:qqplot:lv914 width="80%"}


#### LV-trait associations in real data

![
**QQ-plots of LV-trait associations in real data.**
QQ-plot in PhenomeXcan (left, discovery cohort) across 4,091 traits and 987 LVs, and eMERGE (right, replication cohort) across 309 traits and 987 LVs.
](images/gls/real_data/qqplots.png "QQ-plots in real data"){#fig:reg:real:qqplots width="80%"}


### CRISPR-Cas9

#### Screening steps

![
**EVOS Fluorescent Microscope Image Capture.**
A. HepG2_lentiV2_Ctrl with no-viral transduction.
B. HepG2_lentiV2 with viral transduction.
<!--  -->
](images/crispr/figure1.png "EVOS Fluorescent Microscope Image Capture"){#fig:sup:crispr:fig1 tag="S1" width="80%"}


![
**Fluorescence-Activated Cell Sorting Gate Setting.**
A. HepG2_UnStained WT.
B. HepG2_lentiV2 with viral transduction.
<!--  -->
](images/crispr/figure2.png "Fluorescence-Activated Cell Sorting Gate Setting"){#fig:sup:crispr:fig2 tag="S2" width="80%"}


![
**Verification of sgRNA cassette and lentiV2 transgene.**
A. 20nt sgRNA cassette was verified in lentiV2 transduced genomic DNA population, 163 bp PCR product obtained, while WT HepG2 didn’t possess the cassette, thus, no PCR product.
B. lentiviral-specific transgene WPRE was verified in lentiV2 transduced genomic DNA population, while no transduced WT didn’t have the transgene, therefore, no 173 bp PCR product observed.
<!--  -->
](images/crispr/figure3.png "Verification of sgRNA cassette and lentiV2 transgene"){#fig:sup:crispr:fig3 tag="S3" width="80%"}


![
<!-- **XXX.** -->
<!--  -->
<!--  -->
](images/crispr/table1.png "Table 1"){#fig:sup:crispr:table1 tag="S4" width="80%"}


![
**Illumina library generation.**
A. Construct for generating illumina libraries.
B. Final illumina library from HS DNA ---showed a single ~285bp peak was generated.
](images/crispr/figure4.png "xxxx"){#fig:sup:crispr:fig4 tag="S5" width="80%"}



#### Gene modules enrichment for lipids gene-sets

<!-- lipids_gene_sets:modules_enriched_increase:start -->
| Gene module   | Lipids gene-set   | Leading edge      | p-value   |
|:--------------|:------------------|:------------------|:----------|
| **LV246**     | increase          | *DGAT2*, *ACACA*  | 0.0035    |
| LV702         | increase          | *ACACA*, *DGAT2*  | 0.0046    |
| **LV607**     | increase          | *ACACA*, *DGAT2*  | 0.0058    |
| LV890         | increase          | *ACACA*, *DGAT2*  | 0.0067    |
| **LV74**      | increase          | *MBTPS1*, *DGAT2* | 0.0078    |
| **LV865**     | increase          | *ACACA*, *DGAT2*  | 0.0092    |
| LV841         | increase          | *ACACA*, *DGAT2*  | 0.0096    |

Table: Gene modules (LVs) nominally enriched for the lipids-increasing gene-set from the CRISPR-screen (*P* < 0.01). LVs significantly aligned with pathways (FDR < 0.05) from the MultiPLIER models are shown in boldface. {#tbl:sup:lipids_crispr:modules_enriched_increase}
<!-- lipids_gene_sets:modules_enriched_increase:end -->


<!-- lipids_gene_sets:modules_enriched_decrease:start -->
| Gene module   | Lipids gene-set   | Leading edge       | p-value   |
|:--------------|:------------------|:-------------------|:----------|
| LV520         | decrease          | *FBXW7*, *TCF7L2*  | 0.0006    |
| LV801         | decrease          | *UBE2J2*, *TCF7L2* | 0.0022    |
| LV512         | decrease          | *FBXW7*, *TCF7L2*  | 0.0025    |
| **LV612**     | decrease          | *PTEN*, *FBXW7*    | 0.0036    |
| LV41          | decrease          | *PCYT2*, *TCF7L2*  | 0.0041    |
| **LV838**     | decrease          | *UBE2J2*, *TCF7L2* | 0.0070    |
| LV302         | decrease          | *TCF7L2*, *PTEN*   | 0.0083    |
| LV959         | decrease          | *TCF7L2*, *PTEN*   | 0.0092    |

Table: Gene modules (LVs) nominally enriched for the lipids-decreasing gene-set from the CRISPR-screen (*P* < 0.01). LVs significantly aligned with pathways (FDR < 0.05) from the MultiPLIER models are shown in boldface. {#tbl:sup:lipids_crispr:modules_enriched_decrease}
<!-- lipids_gene_sets:modules_enriched_decrease:end -->



### Consensus clustering of traits

#### Agreement of consensus clustering partitions with the ensemble

![
**Final selected partitions for follow-up analysis.**
<!--  -->
From all consensus clustering partitions generated with $k$ from 2 to 60, we selected those with a median adjusted Rand index (ARI) with the ensemble members greater the 75th percentile.
](images/clustering/selected_best_partitions_by_k.svg "Consensus partitions agreement with ensemble"){#fig:sup:consensus_agreement width="80%"}



#### Cluster-specific and general transcriptional processes associated with disease

![
**Cluster-specific and general transcriptional processes associated with disease using novel LVs.**
The plot shows a submatrix of $\hat{\mathbf{M}}$ for the main trait clusters at $k$=29, considering only LVs (rows) that are not aligned with any pathway.
Standardized values from -6 (lighter color) to 21 (darker color).
](images/clustering/global_clustermap-novel-plain.svg "Heatmap with novel gene modules and traits"){#fig:sup:clustering:novel:heatmap width="100%"}



### Latent variables (gene modules) information

#### LV603

<!-- LV603:multiplier_pathways:start -->
| Pathway                             | AUC   | FDR      |
|:------------------------------------|:------|:---------|
| IRIS Neutrophil-Resting             | 0.91  | 4.51e-35 |
| SVM Neutrophils                     | 0.98  | 1.43e-09 |
| PID IL8CXCR2 PATHWAY                | 0.81  | 7.04e-03 |
| SIG PIP3 SIGNALING IN B LYMPHOCYTES | 0.77  | 1.95e-02 |

Table: Pathways aligned to LV603 from the MultiPLIER models. {#tbl:sup:multiplier_pathways:lv603}
<!-- LV603:multiplier_pathways:end -->

<!-- LV603:phenomexcan_traits_assocs:start -->
| Trait description                         | Sample size   | Cases   | FDR            |
|:------------------------------------------|:--------------|:--------|:---------------|
| Basophill percentage                      | 349,861       |         | 1.19e&#8209;10 |
| Basophill count                           | 349,856       |         | 1.89e&#8209;05 |
| Treatment/medication code: ispaghula husk | 361,141       | 327     | 1.36e&#8209;02 |

Table: Significant trait associations of LV603 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv603}
<!-- LV603:phenomexcan_traits_assocs:end -->

<!-- LV603:emerge_traits_assocs:start -->
| Phecode                     | Trait description   | Sample size   | Cases   | FDR   |
|:----------------------------|:--------------------|:--------------|:--------|:------|
| No significant associations |                     |               |         |       |

Table: Significant trait associations of LV603 in eMERGE. {#tbl:sup:emerge_assocs:lv603}
<!-- LV603:emerge_traits_assocs:end -->


#### LV246

<!-- LV246:multiplier_pathways:start -->
| Pathway                                                        | AUC   | FDR      |
|:---------------------------------------------------------------|:------|:---------|
| REACTOME FATTY ACID TRIACYLGLYCEROL AND KETONE BODY METABOLISM | 0.89  | 3.97e-16 |
| REACTOME METABOLISM OF LIPIDS AND LIPOPROTEINS                 | 0.67  | 1.14e-08 |
| REACTOME TRIGLYCERIDE BIOSYNTHESIS                             | 0.86  | 6.52e-04 |
| KEGG PYRUVATE METABOLISM                                       | 0.82  | 2.66e-03 |
| KEGG PROPANOATE METABOLISM                                     | 0.83  | 4.27e-03 |

Table: Pathways aligned to LV246 from the MultiPLIER models. {#tbl:sup:multiplier_pathways:lv246}
<!-- LV246:multiplier_pathways:end -->

<!-- LV246:phenomexcan_traits_assocs:start -->
| Trait description                                                                          | Sample size   | Cases   | FDR            |
|:-------------------------------------------------------------------------------------------|:--------------|:--------|:---------------|
| Triglycerides NMR                                                                          | 21,559        |         | 1.66e&#8209;26 |
| LDL Cholesterol NMR                                                                        | 13,527        |         | 3.92e&#8209;26 |
| High cholesterol (self-reported)                                                           | 361,141       | 43,957  | 1.08e&#8209;24 |
| Cholesterol lowering medication                                                            | 193,148       | 24,247  | 4.28e&#8209;24 |
| Treatment/medication code: simvastatin                                                     | 361,141       | 40,921  | 2.56e&#8209;19 |
| CH2DB NMR                                                                                  | 24,154        |         | 1.05e&#8209;15 |
| Cholesterol lowering medication                                                            | 165,340       | 38,057  | 9.58e&#8209;15 |
| Treatment/medication code: atorvastatin                                                    | 361,141       | 10,805  | 2.54e&#8209;14 |
| Illnesses of mother: Alzheimer's disease/dementia                                          | 331,041       | 28,507  | 2.76e&#8209;08 |
| Illnesses of father: Alzheimer's disease/dementia                                          | 312,666       | 15,022  | 2.76e&#8209;08 |
| Alzheimers Disease                                                                         | 54,162        | 17,008  | 1.10e&#8209;07 |
| Non-butter spread type details: Flora Pro-Active or Benecol                                | 190,094       | 29,048  | 5.63e&#8209;07 |
| Illnesses of siblings: Alzheimer's disease/dementia                                        | 279,062       | 1,609   | 6.16e&#8209;07 |
| Any dementia                                                                               | 361,194       | 243     | 2.86e&#8209;05 |
| Illnesses of father: None of the above (group 1)                                           | 314,797       | 116,736 | 3.56e&#8209;05 |
| Medication for cholesterol, blood pressure, diabetes, or take exogenous hormones (females) | 193,148       | 133,338 | 1.10e&#8209;04 |
| Treatment/medication code: lipitor 10mg tablet                                             | 361,141       | 2,584   | 1.55e&#8209;04 |
| Treatment/medication code: rosuvastatin                                                    | 361,141       | 2,227   | 1.37e&#8209;03 |
| Illnesses of father: Heart disease                                                         | 318,570       | 104,110 | 1.89e&#8209;03 |
| Dementia                                                                                   | 361,194       | 157     | 9.58e&#8209;03 |
| Mother still alive                                                                         | 355,029       | 140,246 | 1.76e&#8209;02 |
| Job SOC coding: Librarians                                                                 | 91,149        | 1,248   | 3.22e&#8209;02 |
| Alzheimer’s disease                                                                        | 361,194       | 119     | 3.61e&#8209;02 |

Table: Significant trait associations of LV246 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv246}
<!-- LV246:phenomexcan_traits_assocs:end -->

<!-- LV246:emerge_traits_assocs:start -->
| Phecode   | Trait description              | Sample size   | Cases   | FDR            |
|:----------|:-------------------------------|:--------------|:--------|:---------------|
| 272.11    | Hypercholesterolemia           | 40,786        | 14,138  | 4.40e&#8209;09 |
| 272.1     | Hyperlipidemia                 | 55,843        | 29,195  | 3.57e&#8209;07 |
| 272       | Disorders of lipoid metabolism | 55,892        | 29,244  | 3.79e&#8209;07 |
| 292.3     | Memory loss                    | 48,785        | 2,094   | 1.80e&#8209;02 |

Table: Significant trait associations of LV246 in eMERGE. {#tbl:sup:emerge_assocs:lv246}
<!-- LV246:emerge_traits_assocs:end -->


#### LV116

<!-- LV116:multiplier_pathways:start -->
| Pathway                                              | AUC   | FDR      |
|:-----------------------------------------------------|:------|:---------|
| REACTOME INTERFERON SIGNALING                        | 0.84  | 3.48e-09 |
| SVM Macrophages M1                                   | 0.92  | 2.09e-05 |
| REACTOME INTERFERON ALPHA BETA SIGNALING             | 0.94  | 3.36e-05 |
| REACTOME CYTOKINE SIGNALING IN IMMUNE SYSTEM         | 0.67  | 1.53e-04 |
| IRIS DendriticCell-LPSstimulated                     | 0.65  | 1.09e-03 |
| KEGG CYTOSOLIC DNA SENSING PATHWAY                   | 0.84  | 3.22e-03 |
| REACTOME NEGATIVE REGULATORS OF RIG I MDA5 SIGNALING | 0.81  | 1.61e-02 |

Table: Pathways aligned to LV116 from the MultiPLIER models. {#tbl:sup:multiplier_pathways:lv116}
<!-- LV116:multiplier_pathways:end -->


#### LV931

![
**Cell types for LV931.**
<!--  -->
](images/lvs_analysis/lv931/lv931-cell_types.svg "Cell types for LV931"){#fig:sup:lv931 width="80%"}


<!-- LV931:multiplier_pathways:start -->
| Pathway          | AUC   | FDR      |
|:-----------------|:------|:---------|
| MIPS SPLICEOSOME | 0.63  | 3.13e-02 |
| PID TGFBRPATHWAY | 0.71  | 3.99e-02 |

Table: Pathways aligned to LV931 from the MultiPLIER models. {#tbl:sup:multiplier_pathways:lv931}
<!-- LV931:multiplier_pathways:end -->


#### LV66

![
**Cell types for LV66.**
<!--  -->
](images/lvs_analysis/lv66/lv66-cell_types.svg "Cell types for LV66"){#fig:sup:lv66 width="80%"}

<!-- LV66:multiplier_pathways:start -->
| Pathway                                        | AUC   | FDR      |
|:-----------------------------------------------|:------|:---------|
| REACTOME METABOLISM OF LIPIDS AND LIPOPROTEINS | 0.62  | 3.12e-04 |

Table: Pathways aligned to LV66 from the MultiPLIER models. {#tbl:sup:multiplier_pathways:lv66}
<!-- LV66:multiplier_pathways:end -->


#### LV928

![
**Cell types for LV928.**
<!--  -->
](images/lvs_analysis/lv928/lv928-cell_types.svg "Cell types for LV928"){#fig:sup:lv928 width="80%"}

<!-- LV928:multiplier_pathways:start -->
| Pathway   | AUC   | FDR      |
|:----------|:------|:---------|
| DMAP ERY3 | 0.81  | 1.16e-24 |
| DMAP ERY4 | 0.78  | 2.49e-17 |

Table: Pathways aligned to LV928 from the MultiPLIER models. {#tbl:sup:multiplier_pathways:lv928}
<!-- LV928:multiplier_pathways:end -->

<!-- LV928:phenomexcan_traits_assocs:start -->
| Trait description                               | Sample size   | Cases   | Partition / cluster   | FDR            |
|:------------------------------------------------|:--------------|:--------|:----------------------|:---------------|
| Mean sphered cell volume                        | 344,729       |         | 29 / 2                | 2.18e&#8209;46 |
| Mean reticulocyte volume                        | 344,728       |         | 29 / 2                | 4.08e&#8209;44 |
| Mean corpuscular volume                         | 350,473       |         | 29 / 2                | 5.57e&#8209;33 |
| Red blood cell (erythrocyte) distribution width | 350,473       |         | 29 / 23               | 7.62e&#8209;31 |
| Reticulocyte percentage                         | 344,728       |         | 29 / 4                | 2.12e&#8209;29 |
| Reticulocyte count                              | 344,729       |         | 29 / 4                | 6.88e&#8209;28 |
| Reticulocyte Count                              | 173,480       |         | 29 / 4                | 1.06e&#8209;23 |
| Mean corpuscular haemoglobin                    | 350,472       |         | 29 / 2                | 7.89e&#8209;23 |
| High light scatter reticulocyte count           | 344,729       |         | 29 / 4                | 3.05e&#8209;21 |
| Immature reticulocyte fraction                  | 344,728       |         | 29 / 4                | 5.04e&#8209;21 |
| High light scatter reticulocyte percentage      | 344,729       |         | 29 / 4                | 1.57e&#8209;16 |
| Red blood cell (erythrocyte) count              | 350,475       |         | 29 / 5                | 2.53e&#8209;16 |
| Red Blood Cell Count                            | 173,480       |         | 29 / 5                | 2.62e&#8209;09 |
| Haemoglobin concentration                       | 350,474       |         | 29 / 5                | 1.25e&#8209;03 |
| Haematocrit percentage                          | 350,475       |         | 29 / 5                | 3.77e&#8209;03 |

Table: Significant trait associations of LV928 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv928}
<!-- LV928:phenomexcan_traits_assocs:end -->

<!-- LV928:emerge_traits_assocs:start -->
| Phecode   | Trait description                                | Sample size   | Cases   | FDR            |
|:----------|:-------------------------------------------------|:--------------|:--------|:---------------|
| 250.24    | Type 2 diabetes with neurological manifestations | 43,236        | 2,963   | 1.44e&#8209;02 |
| 195       | Cancer, suspected or other                       | 50,040        | 2,250   | 2.42e&#8209;02 |
| 514.2     | Solitary pulmonary nodule                        | 50,389        | 2,270   | 4.65e&#8209;02 |

Table: Significant trait associations of LV928 in eMERGE. {#tbl:sup:emerge_assocs:lv928}
<!-- LV928:emerge_traits_assocs:end -->


#### LV30

![
**Cell types for LV30.**
<!--  -->
](images/lvs_analysis/lv30/lv30-cell_types.svg "Cell types for LV30"){#fig:sup:lv30 width="80%"}

<!-- LV30:multiplier_pathways:start -->
| Pathway   | AUC   | FDR      |
|:----------|:------|:---------|
| DMAP ERY3 | 0.95  | 5.62e-52 |
| DMAP ERY4 | 0.98  | 5.28e-51 |
| DMAP ERY5 | 0.98  | 1.96e-49 |

Table: Pathways aligned to LV30 from the MultiPLIER models. {#tbl:sup:multiplier_pathways:lv30}
<!-- LV30:multiplier_pathways:end -->

<!-- LV30:phenomexcan_traits_assocs:start -->
| Trait description                          | Sample size   | Cases   | Partition / cluster   | FDR            |
|:-------------------------------------------|:--------------|:--------|:----------------------|:---------------|
| Mean reticulocyte volume                   | 344,728       |         | 29 / 2                | 1.41e&#8209;51 |
| Immature reticulocyte fraction             | 344,728       |         | 29 / 4                | 5.79e&#8209;40 |
| Mean sphered cell volume                   | 344,729       |         | 29 / 2                | 3.26e&#8209;36 |
| Mean corpuscular volume                    | 350,473       |         | 29 / 2                | 3.18e&#8209;35 |
| Reticulocyte percentage                    | 344,728       |         | 29 / 4                | 1.41e&#8209;28 |
| Mean corpuscular haemoglobin               | 350,472       |         | 29 / 2                | 3.72e&#8209;28 |
| High light scatter reticulocyte count      | 344,729       |         | 29 / 4                | 8.20e&#8209;28 |
| Reticulocyte count                         | 344,729       |         | 29 / 4                | 2.13e&#8209;26 |
| Reticulocyte Count                         | 173,480       |         | 29 / 4                | 1.11e&#8209;24 |
| High light scatter reticulocyte percentage | 344,729       |         | 29 / 4                | 4.05e&#8209;22 |

Table: Significant trait associations of LV30 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv30}
<!-- LV30:phenomexcan_traits_assocs:end -->

<!-- LV30:emerge_traits_assocs:start -->
| Phecode                     | Trait description   | Sample size   | Cases   | FDR   |
|:----------------------------|:--------------------|:--------------|:--------|:------|
| No significant associations |                     |               |         |       |

Table: Significant trait associations of LV30 in eMERGE. {#tbl:sup:emerge_assocs:lv30}
<!-- LV30:emerge_traits_assocs:end -->


#### LV730

![
**Cell types for LV730.**
<!--  -->
](images/lvs_analysis/lv730/lv730-cell_types.svg "Cell types for LV730"){#fig:sup:lv730 width="80%"}

<!-- LV730:multiplier_pathways:start -->
| Pathway    | AUC   | FDR      |
|:-----------|:------|:---------|
| DMAP MEGA2 | 0.82  | 2.64e-05 |

Table: Pathways aligned to LV730 from the MultiPLIER models. {#tbl:sup:multiplier_pathways:lv730}
<!-- LV730:multiplier_pathways:end -->

<!-- LV730:phenomexcan_traits_assocs:start -->
| Trait description                  | Sample size   | Cases   | Partition / cluster   | FDR            |
|:-----------------------------------|:--------------|:--------|:----------------------|:---------------|
| Platelet distribution width        | 350,470       |         | 29 / 1                | 2.88e&#8209;13 |
| Mean platelet (thrombocyte) volume | 350,470       |         | 29 / 1                | 7.26e&#8209;13 |
| Platelet count                     | 350,474       |         | 29 / 1                | 1.24e&#8209;07 |
| Platelet Count                     | 173,480       |         | 29 / 1                | 1.21e&#8209;06 |
| Platelet crit                      | 350,471       |         | 29 / 1                | 1.38e&#8209;04 |

Table: Significant trait associations of LV730 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv730}
<!-- LV730:phenomexcan_traits_assocs:end -->

<!-- LV730:emerge_traits_assocs:start -->
| Phecode                     | Trait description   | Sample size   | Cases   | FDR   |
|:----------------------------|:--------------------|:--------------|:--------|:------|
| No significant associations |                     |               |         |       |

Table: Significant trait associations of LV730 in eMERGE. {#tbl:sup:emerge_assocs:lv730}
<!-- LV730:emerge_traits_assocs:end -->


#### LV598

![
**Cell types for LV598.**
<!--  -->
](images/lvs_analysis/lv598/lv598-cell_types.svg "Cell types for LV598"){#fig:sup:lv598 width="80%"}

<!-- LV598:multiplier_pathways:start -->
| Pathway                     | AUC   | FDR      |
|:----------------------------|:------|:---------|
| PID SYNDECAN 1 PATHWAY      | 0.81  | 1.20e-02 |
| REACTOME COLLAGEN FORMATION | 0.77  | 1.89e-02 |

Table: Pathways aligned to LV598 from the MultiPLIER models. {#tbl:sup:multiplier_pathways:lv598}
<!-- LV598:multiplier_pathways:end -->

<!-- LV598:phenomexcan_traits_assocs:start -->
| Trait description           | Sample size   | Cases   | Partition / cluster   | FDR            |
|:----------------------------|:--------------|:--------|:----------------------|:---------------|
| 6mm strong meridian (right) | 66,256        |         | 29 / 10               | 3.21e&#8209;07 |
| 6mm weak meridian (right)   | 66,256        |         | 29 / 10               | 2.04e&#8209;06 |
| 6mm strong meridian (left)  | 65,551        |         | 29 / 10               | 2.44e&#8209;06 |
| 3mm strong meridian (left)  | 75,398        |         | 29 / 10               | 2.53e&#8209;06 |
| 6mm weak meridian (left)    | 65,551        |         | 29 / 10               | 1.20e&#8209;05 |
| 3mm weak meridian (left)    | 75,398        |         | 29 / 10               | 1.58e&#8209;05 |
| 3mm strong meridian (right) | 75,410        |         | 29 / 10               | 2.95e&#8209;05 |
| 3mm weak meridian (right)   | 75,410        |         | 29 / 10               | 3.86e&#8209;05 |

Table: Significant trait associations of LV598 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv598}
<!-- LV598:phenomexcan_traits_assocs:end -->

<!-- LV598:emerge_traits_assocs:start -->
| Phecode                     | Trait description   | Sample size   | Cases   | FDR   |
|:----------------------------|:--------------------|:--------------|:--------|:------|
| No significant associations |                     |               |         |       |

Table: Significant trait associations of LV598 in eMERGE. {#tbl:sup:emerge_assocs:lv598}
<!-- LV598:emerge_traits_assocs:end -->


#### LV844

![
**Cell types for LV844.**
](images/lvs_analysis/lv844/lv844-cell_types.svg "Cell types for LV844"){#fig:sup:lv844 width="80%"}

<!-- LV844:multiplier_pathways:start -->
| Pathway                                  | AUC   | FDR      |
|:-----------------------------------------|:------|:---------|
| KEGG ANTIGEN PROCESSING AND PRESENTATION | 0.80  | 1.35e-03 |

Table: Pathways aligned to LV844 from the MultiPLIER models. {#tbl:sup:multiplier_pathways:lv844}
<!-- LV844:multiplier_pathways:end -->

<!-- LV844:phenomexcan_traits_assocs:start -->
| Trait description                                     | Sample size   | Cases   | Partition / cluster   | FDR            |
|:------------------------------------------------------|:--------------|:--------|:----------------------|:---------------|
| Rheumatoid Arthritis                                  | 80,799        | 19,234  | 29 / 26               | 1.20e&#8209;57 |
| malabsorption/coeliac disease (self-reported)         | 361,141       | 1,587   | 29 / 8                | 1.25e&#8209;43 |
| Coeliac disease                                       | 361,194       | 842     | 29 / 8                | 1.52e&#8209;41 |
| Intestinal malabsorption (ICD10 K90)                  | 361,194       | 922     | 29 / 8                | 5.28e&#8209;40 |
| Started insulin within one year diagnosis of diabetes | 16,415        | 1,999   | 29 / 13               | 7.77e&#8209;38 |
| Systemic Lupus Erythematosus                          | 23,210        | 7,219   | 29 / 26               | 6.45e&#8209;35 |
| Age diabetes diagnosed                                | 16,166        |         | 29 / 13               | 1.92e&#8209;34 |
| Never eat: Wheat products                             | 359,777       | 9,573   | 29 / 13               | 1.37e&#8209;31 |
| hyperthyroidism (self-reported)                       | 361,141       | 2,730   | 29 / 13               | 3.41e&#8209;30 |
| Medication: insulin product                           | 361,141       | 3,545   | 29 / 13               | 1.78e&#8209;25 |
| Insulin medication (females)                          | 193,148       | 1,476   | 29 / 13               | 2.79e&#8209;23 |
| Insulin medication (males)                            | 165,340       | 2,248   | 29 / 13               | 1.27e&#8209;20 |
| hypothyroidism (self-reported)                        | 361,141       | 17,574  | 29 / 13               | 3.35e&#8209;20 |
| Medication: levothyroxine sodium                      | 361,141       | 14,689  | 29 / 13               | 2.76e&#8209;19 |
| psoriasis (self-reported)                             | 361,141       | 4,192   | 29 / 13               | 6.74e&#8209;16 |

Table: Significant trait associations of LV844 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv844}
<!-- LV844:phenomexcan_traits_assocs:end -->

<!-- LV844:emerge_traits_assocs:start -->
| Phecode   | Trait description                                                                    | Sample size   | Cases   | FDR            |
|:----------|:-------------------------------------------------------------------------------------|:--------------|:--------|:---------------|
| 714.1     | Rheumatoid arthritis                                                                 | 49,453        | 2,541   | 1.53e&#8209;08 |
| 250.1     | Type 1 diabetes                                                                      | 42,723        | 2,450   | 3.85e&#8209;08 |
| 714       | Rheumatoid arthritis and other inflammatory polyarthropathies                        | 50,215        | 3,303   | 1.02e&#8209;06 |
| 440       | Atherosclerosis                                                                      | 47,471        | 4,993   | 6.73e&#8209;03 |
| 578.8     | Hemorrhage of rectum and anus                                                        | 47,545        | 1,991   | 6.73e&#8209;03 |
| 585.32    | End stage renal disease                                                              | 43,309        | 1,842   | 9.01e&#8209;03 |
| 440.2     | Atherosclerosis of the extremities                                                   | 45,524        | 3,046   | 1.09e&#8209;02 |
| 514.2     | Solitary pulmonary nodule                                                            | 50,389        | 2,270   | 1.39e&#8209;02 |
| 444       | Arterial embolism and thrombosis                                                     | 43,378        | 900     | 2.97e&#8209;02 |
| 440.22    | Atherosclerosis of native arteries of the extremities with intermittent claudication | 44,639        | 2,161   | 3.61e&#8209;02 |

Table: Significant trait associations of LV844 in eMERGE. {#tbl:sup:emerge_assocs:lv844}
<!-- LV844:emerge_traits_assocs:end -->


#### LV155

![
**Cell types for LV155.**
<!--  -->
](images/lvs_analysis/lv155/lv155-cell_types.svg "Cell types for LV155"){#fig:sup:lv155 width="80%"}

<!-- LV155:multiplier_pathways:start -->
| Pathway                            | AUC   | FDR   |
|:-----------------------------------|:------|:------|
| No pathways significantly enriched |       |       |

Table: Pathways aligned to LV155 from the MultiPLIER models. {#tbl:sup:multiplier_pathways:lv155}
<!-- LV155:multiplier_pathways:end -->

<!-- LV155:phenomexcan_traits_assocs:start -->
| Trait description                | Sample size   | Cases   | Partition / cluster   | FDR            |
|:---------------------------------|:--------------|:--------|:----------------------|:---------------|
| hypothyroidism (self-reported)   | 361,141       | 17,574  | 29 / 13               | 1.65e&#8209;03 |
| hyperthyroidism (self-reported)  | 361,141       | 2,730   | 29 / 13               | 1.03e&#8209;02 |
| Medication: levothyroxine sodium | 361,141       | 14,689  | 29 / 13               | 1.12e&#8209;02 |

Table: Significant trait associations of LV155 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv155}
<!-- LV155:phenomexcan_traits_assocs:end -->

<!-- LV155:emerge_traits_assocs:start -->
| Phecode   | Trait description       | Sample size   | Cases   | FDR            |
|:----------|:------------------------|:--------------|:--------|:---------------|
| 244.2     | Acquired hypothyroidism | 45,839        | 1,155   | 5.66e&#8209;02 |

Table: Trait associations of LV155 in eMERGE. {#tbl:sup:emerge_assocs:lv155}
<!-- LV155:emerge_traits_assocs:end -->


#### LV57

![
**Cell types for LV57.**
](images/lvs_analysis/lv57/lv57-cell_types.svg "Cell types for LV57"){#fig:sup:lv57 width="80%"}

<!-- LV57:multiplier_pathways:start -->
| Pathway                                | AUC   | FDR      |
|:---------------------------------------|:------|:---------|
| KEGG T CELL RECEPTOR SIGNALING PATHWAY | 0.70  | 1.26e-03 |
| SVM T cells CD4 memory activated       | 0.79  | 2.59e-03 |
| IRIS CD4Tcell-Th2-restimulated12hour   | 0.78  | 7.57e-03 |
| KEGG ALLOGRAFT REJECTION               | 1.00  | 1.09e-02 |
| Custom Treg                            | 0.98  | 1.37e-02 |
| PID NFAT TFPATHWAY                     | 0.74  | 1.52e-02 |
| IRIS MemoryTcell-RO-activated          | 0.70  | 2.87e-02 |

Table: Pathways aligned to LV57 from the MultiPLIER models. {#tbl:sup:multiplier_pathways:lv57}
<!-- LV57:multiplier_pathways:end -->

<!-- LV57:phenomexcan_traits_assocs:start -->
| Trait description                                     | Sample size   | Cases   | Partition / cluster   | FDR            |
|:------------------------------------------------------|:--------------|:--------|:----------------------|:---------------|
| hypothyroidism (self-reported)                        | 361,141       | 17,574  | 29 / 13               | 7.21e&#8209;25 |
| Medication: levothyroxine sodium                      | 361,141       | 14,689  | 29 / 13               | 3.71e&#8209;23 |
| hyperthyroidism (self-reported)                       | 361,141       | 2,730   | 29 / 13               | 8.93e&#8209;07 |
| Started insulin within one year diagnosis of diabetes | 16,415        | 1,999   | 29 / 13               | 6.60e&#8209;05 |
| Medication: insulin product                           | 361,141       | 3,545   | 29 / 13               | 5.20e&#8209;04 |
| Insulin medication (females)                          | 193,148       | 1,476   | 29 / 13               | 9.40e&#8209;04 |
| Insulin medication (males)                            | 165,340       | 2,248   | 29 / 13               | 3.63e&#8209;03 |

Table: Significant trait associations of LV57 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv57}
<!-- LV57:phenomexcan_traits_assocs:end -->

<!-- LV57:emerge_traits_assocs:start -->
| Phecode   | Trait description                                             | Sample size   | Cases   | FDR            |
|:----------|:--------------------------------------------------------------|:--------------|:--------|:---------------|
| 244       | Hypothyroidism                                                | 54,404        | 9,720   | 7.66e&#8209;09 |
| 244.4     | Hypothyroidism NOS                                            | 53,968        | 9,284   | 7.66e&#8209;09 |
| 279       | Disorders involving the immune mechanism                      | 56,771        | 3,309   | 1.07e&#8209;02 |
| 514.2     | Solitary pulmonary nodule                                     | 50,389        | 2,270   | 2.62e&#8209;02 |
| 714       | Rheumatoid arthritis and other inflammatory polyarthropathies | 50,215        | 3,303   | 3.77e&#8209;02 |

Table: Significant trait associations of LV57 in eMERGE. {#tbl:sup:emerge_assocs:lv57}
<!-- LV57:emerge_traits_assocs:end -->


#### LV54

![
**Cell types for LV54.**
](images/lvs_analysis/lv54/lv54-cell_types.svg "Cell types for LV54"){#fig:sup:lv54 width="80%"}

<!-- LV54:multiplier_pathways:start -->
| Pathway                            | AUC   | FDR   |
|:-----------------------------------|:------|:------|
| No pathways significantly enriched |       |       |

Table: Pathways aligned to LV54 from the MultiPLIER models. {#tbl:sup:multiplier_pathways:lv54}
<!-- LV54:multiplier_pathways:end -->

<!-- LV54:phenomexcan_traits_assocs:start -->
| Trait description                                     | Sample size   | Cases   | Partition / cluster   | FDR            |
|:------------------------------------------------------|:--------------|:--------|:----------------------|:---------------|
| Intestinal malabsorption (ICD10 K90)                  | 361,194       | 922     | 29 / 8                | 3.10e&#8209;25 |
| Coeliac disease                                       | 361,194       | 842     | 29 / 8                | 4.78e&#8209;25 |
| Never eat: Wheat products                             | 359,777       | 9,573   | 29 / 13               | 3.93e&#8209;23 |
| Systemic Lupus Erythematosus                          | 23,210        | 7,219   | 29 / 26               | 8.16e&#8209;23 |
| Started insulin within one year diagnosis of diabetes | 16,415        | 1,999   | 29 / 13               | 2.57e&#8209;20 |
| hyperthyroidism (self-reported)                       | 361,141       | 2,730   | 29 / 13               | 6.70e&#8209;19 |
| Medication: insulin product                           | 361,141       | 3,545   | 29 / 13               | 3.62e&#8209;18 |
| Age diabetes diagnosed                                | 16,166        |         | 29 / 13               | 9.20e&#8209;18 |
| malabsorption/coeliac disease (self-reported)         | 361,141       | 1,587   | 29 / 8                | 9.63e&#8209;15 |
| Insulin medication (males)                            | 165,340       | 2,248   | 29 / 13               | 6.01e&#8209;14 |
| psoriasis (self-reported)                             | 361,141       | 4,192   | 29 / 13               | 1.81e&#8209;13 |
| Rheumatoid Arthritis                                  | 80,799        | 19,234  | 29 / 26               | 2.17e&#8209;13 |
| Insulin medication (females)                          | 193,148       | 1,476   | 29 / 13               | 2.61e&#8209;12 |
| Medication: levothyroxine sodium                      | 361,141       | 14,689  | 29 / 13               | 4.25e&#8209;10 |
| hypothyroidism (self-reported)                        | 361,141       | 17,574  | 29 / 13               | 2.49e&#8209;08 |

Table: Significant trait associations of LV54 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv54}
<!-- LV54:phenomexcan_traits_assocs:end -->

<!-- LV54:emerge_traits_assocs:start -->
| Phecode   | Trait description                                             | Sample size   | Cases   | FDR            |
|:----------|:--------------------------------------------------------------|:--------------|:--------|:---------------|
| 250.1     | Type 1 diabetes                                               | 42,723        | 2,450   | 1.69e&#8209;13 |
| 244       | Hypothyroidism                                                | 54,404        | 9,720   | 1.01e&#8209;05 |
| 244.4     | Hypothyroidism NOS                                            | 53,968        | 9,284   | 1.01e&#8209;05 |
| 695       | Erythematous conditions                                       | 48,347        | 4,210   | 8.54e&#8209;05 |
| 714       | Rheumatoid arthritis and other inflammatory polyarthropathies | 50,215        | 3,303   | 6.58e&#8209;04 |
| 440       | Atherosclerosis                                               | 47,471        | 4,993   | 1.90e&#8209;03 |
| 585       | Renal failure                                                 | 51,437        | 9,970   | 7.10e&#8209;03 |
| 585.33    | Chronic Kidney Disease, Stage III                             | 46,279        | 4,812   | 7.49e&#8209;03 |
| 585.32    | End stage renal disease                                       | 43,309        | 1,842   | 7.49e&#8209;03 |
| 250.6     | Polyneuropathy in diabetes                                    | 41,948        | 1,675   | 8.55e&#8209;03 |
| 250       | Diabetes mellitus                                             | 52,531        | 12,258  | 1.02e&#8209;02 |
| 285.2     | Anemia of chronic disease                                     | 39,673        | 2,606   | 1.64e&#8209;02 |
| 502       | Postinflammatory pulmonary fibrosis                           | 42,396        | 1,723   | 1.77e&#8209;02 |
| 415.1     | Acute pulmonary heart disease                                 | 49,887        | 1,857   | 1.88e&#8209;02 |
| 285.21    | Anemia in chronic kidney disease                              | 38,616        | 1,549   | 2.53e&#8209;02 |
| 585.3     | Chronic renal failure [CKD]                                   | 49,204        | 7,737   | 2.62e&#8209;02 |
| 743       | Osteoporosis, osteopenia and pathological fracture            | 55,165        | 11,990  | 2.87e&#8209;02 |
| 415.11    | Pulmonary embolism and infarction, acute                      | 49,867        | 1,837   | 3.04e&#8209;02 |
| 577       | Diseases of pancreas                                          | 60,538        | 1,795   | 3.06e&#8209;02 |
| 585.1     | Acute renal failure                                           | 46,803        | 5,336   | 3.23e&#8209;02 |
| 195       | Cancer, suspected or other                                    | 50,040        | 2,250   | 3.27e&#8209;02 |
| 289.4     | Lymphadenitis                                                 | 47,564        | 3,078   | 3.67e&#8209;02 |
| 440.2     | Atherosclerosis of the extremities                            | 45,524        | 3,046   | 4.52e&#8209;02 |

Table: Significant trait associations of LV54 in eMERGE. {#tbl:sup:emerge_assocs:lv54}
<!-- LV54:emerge_traits_assocs:end -->


#### LV847

![
**Cell types for LV847.**
](images/lvs_analysis/lv847/lv847-cell_types.svg "Cell types for LV847"){#fig:sup:lv847 width="80%"}

<!-- LV847:multiplier_pathways:start -->
| Pathway                           | AUC   | FDR      |
|:----------------------------------|:------|:---------|
| KEGG SYSTEMIC LUPUS ERYTHEMATOSUS | 0.74  | 1.86e-04 |
| REACTOME MEIOTIC RECOMBINATION    | 0.78  | 3.60e-04 |
| REACTOME RNA POL I TRANSCRIPTION  | 0.75  | 5.56e-04 |
| REACTOME AMYLOIDS                 | 0.76  | 2.17e-03 |

Table: Pathways aligned to LV847 from the MultiPLIER models. {#tbl:sup:multiplier_pathways:lv847}
<!-- LV847:multiplier_pathways:end -->

<!-- LV847:phenomexcan_traits_assocs:start -->
| Trait description                                                                          | Sample size   | Cases   | Partition / cluster   | FDR            |
|:-------------------------------------------------------------------------------------------|:--------------|:--------|:----------------------|:---------------|
| Mean corpuscular haemoglobin                                                               | 350,472       |         | 29 / 2                | 7.34e&#8209;73 |
| Mean corpuscular volume                                                                    | 350,473       |         | 29 / 2                | 1.43e&#8209;50 |
| Blood pressure medication (females)                                                        | 193,148       | 33,519  | 29 / 17               | 1.38e&#8209;18 |
| Heart attack, angina, stroke or hypertension                                               | 360,420       | 253,565 | 29 / 17               | 2.92e&#8209;15 |
| hypertension                                                                               | 360,420       | 97,139  | 29 / 17               | 4.82e&#8209;14 |
| hypertension (self-reported)                                                               | 361,141       | 93,560  | 29 / 17               | 1.02e&#8209;13 |
| Medication: bendroflumethiazide                                                            | 361,141       | 20,196  | 29 / 17               | 1.06e&#8209;08 |
| Mean sphered cell volume                                                                   | 344,729       |         | 29 / 2                | 2.16e&#8209;08 |
| Blood pressure medication (males)                                                          | 165,340       | 40,987  | 29 / 17               | 1.14e&#8209;07 |
| Medication for cholesterol, blood pressure, diabetes, or take exogenous hormones (females) | 193,148       | 133,338 | 29 / 17               | 1.21e&#8209;06 |
| Diastolic blood pressure, automated reading                                                | 340,162       |         | 29 / 17               | 2.93e&#8209;06 |
| Medication for cholesterol, blood pressure or diabetes (males)                             | 165,340       | 110,372 | 29 / 17               | 5.01e&#8209;06 |
| Mean reticulocyte volume                                                                   | 344,728       |         | 29 / 2                | 8.38e&#8209;03 |

Table: Significant trait associations of LV847 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv847}
<!-- LV847:phenomexcan_traits_assocs:end -->

<!-- LV847:emerge_traits_assocs:start -->
| Phecode   | Trait description                                                                    | Sample size   | Cases   | FDR            |
|:----------|:-------------------------------------------------------------------------------------|:--------------|:--------|:---------------|
| 585.32    | End stage renal disease                                                              | 43,309        | 1,842   | 3.11e&#8209;08 |
| 443       | Peripheral vascular disease                                                          | 47,867        | 5,389   | 4.13e&#8209;06 |
| 442.1     | Aortic aneurysm                                                                      | 45,589        | 3,111   | 1.01e&#8209;05 |
| 411.3     | Angina pectoris                                                                      | 43,503        | 4,382   | 4.28e&#8209;05 |
| 440.2     | Atherosclerosis of the extremities                                                   | 45,524        | 3,046   | 6.57e&#8209;05 |
| 415.11    | Pulmonary embolism and infarction, acute                                             | 49,867        | 1,837   | 9.90e&#8209;05 |
| 416       | Cardiomegaly                                                                         | 53,289        | 5,259   | 1.34e&#8209;04 |
| 415.1     | Acute pulmonary heart disease                                                        | 49,887        | 1,857   | 1.49e&#8209;04 |
| 599.3     | Dysuria                                                                              | 42,858        | 3,581   | 1.74e&#8209;04 |
| 585       | Renal failure                                                                        | 51,437        | 9,970   | 3.90e&#8209;04 |
| 411       | Ischemic Heart Disease                                                               | 54,275        | 15,154  | 1.19e&#8209;03 |
| 531       | Peptic ulcer (excl. esophageal)                                                      | 59,472        | 1,561   | 2.26e&#8209;03 |
| 250.6     | Polyneuropathy in diabetes                                                           | 41,948        | 1,675   | 2.32e&#8209;03 |
| 443.9     | Peripheral vascular disease, unspecified                                             | 46,926        | 4,448   | 2.40e&#8209;03 |
| 519       | Other diseases of respiratory system, not elsewhere classified                       | 56,909        | 2,056   | 2.43e&#8209;03 |
| 401.2     | Hypertensive heart and/or renal disease                                              | 30,405        | 6,253   | 2.43e&#8209;03 |
| 411.8     | Other chronic ischemic heart disease, unspecified                                    | 44,123        | 5,002   | 2.71e&#8209;03 |
| 440.22    | Atherosclerosis of native arteries of the extremities with intermittent claudication | 44,639        | 2,161   | 2.97e&#8209;03 |
| 401.22    | Hypertensive chronic kidney disease                                                  | 28,944        | 4,792   | 5.61e&#8209;03 |
| 514       | Abnormal findings examination of lungs                                               | 54,668        | 6,549   | 6.96e&#8209;03 |
| 427.6     | Premature beats                                                                      | 31,575        | 2,453   | 1.27e&#8209;02 |
| 585.1     | Acute renal failure                                                                  | 46,803        | 5,336   | 1.39e&#8209;02 |
| 418       | Nonspecific chest pain                                                               | 51,082        | 17,765  | 1.39e&#8209;02 |
| 250.1     | Type 1 diabetes                                                                      | 42,723        | 2,450   | 1.44e&#8209;02 |
| 285.21    | Anemia in chronic kidney disease                                                     | 38,616        | 1,549   | 1.82e&#8209;02 |
| 368       | Visual disturbances                                                                  | 56,141        | 2,694   | 1.88e&#8209;02 |
| 427.5     | Arrhythmia (cardiac) NOS                                                             | 36,861        | 7,739   | 2.01e&#8209;02 |
| 687.1     | Rash and other nonspecific skin eruption                                             | 47,039        | 4,964   | 2.15e&#8209;02 |
| 185       | Cancer of prostate                                                                   | 52,630        | 2,815   | 2.31e&#8209;02 |
| 747       | Cardiac and circulatory congenital anomalies                                         | 59,494        | 2,167   | 2.47e&#8209;02 |
| 444       | Arterial embolism and thrombosis                                                     | 43,378        | 900     | 2.53e&#8209;02 |
| 585.3     | Chronic renal failure [CKD]                                                          | 49,204        | 7,737   | 2.53e&#8209;02 |
| 440       | Atherosclerosis                                                                      | 47,471        | 4,993   | 2.62e&#8209;02 |
| 591       | Urinary tract infection                                                              | 49,727        | 10,016  | 2.94e&#8209;02 |
| 411.1     | Unstable angina (intermediate coronary syndrome)                                     | 41,763        | 2,642   | 3.06e&#8209;02 |
| 285.2     | Anemia of chronic disease                                                            | 39,673        | 2,606   | 3.06e&#8209;02 |
| 274.1     | Gout                                                                                 | 59,252        | 3,394   | 3.23e&#8209;02 |
| 585.34    | Chronic Kidney Disease, Stage IV                                                     | 43,322        | 1,855   | 3.84e&#8209;02 |
| 452       | Other venous embolism and thrombosis                                                 | 40,476        | 3,816   | 4.49e&#8209;02 |
| 427.12    | Paroxysmal ventricular tachycardia                                                   | 31,154        | 2,032   | 4.52e&#8209;02 |

Table: Significant trait associations of LV847 in eMERGE. {#tbl:sup:emerge_assocs:lv847}
<!-- LV847:emerge_traits_assocs:end -->


#### LV136

![
**Cell types for LV136.**
<!--  -->
Pulmonary microvascular endothelial cells were exposed to hypoxia for 24 hours or more [@url:https://www.ncbi.nlm.nih.gov/bioproject/PRJNA232177];
](images/lvs_analysis/lv136/lv136-cell_types.svg "Cell types for LV136"){#fig:sup:lv136 width="80%"}

<!-- LV136:multiplier_pathways:start -->
| Pathway                       | AUC   | FDR      |
|:------------------------------|:------|:---------|
| PID INTEGRIN1 PATHWAY         | 0.88  | 9.35e-06 |
| KEGG ECM RECEPTOR INTERACTION | 0.80  | 7.29e-05 |
| REACTOME COLLAGEN FORMATION   | 0.87  | 2.00e-04 |
| REACTOME MUSCLE CONTRACTION   | 0.75  | 1.49e-02 |

Table: Pathways aligned to LV136 from the MultiPLIER models. {#tbl:sup:multiplier_pathways:lv136}
<!-- LV136:multiplier_pathways:end -->

<!-- LV136:phenomexcan_traits_assocs:start -->
| Trait description                                  | Sample size   | Cases   | Partition / cluster   | FDR            |
|:---------------------------------------------------|:--------------|:--------|:----------------------|:---------------|
| 3mm strong meridian (right)                        | 75,410        |         | 29 / 10               | 6.37e&#8209;11 |
| 6mm strong meridian (left)                         | 65,551        |         | 29 / 10               | 1.53e&#8209;09 |
| 6mm strong meridian (right)                        | 66,256        |         | 29 / 10               | 1.78e&#8209;09 |
| 3mm strong meridian (left)                         | 75,398        |         | 29 / 10               | 9.90e&#8209;09 |
| Coronary Artery Disease                            | 184,305       | 60,801  | 29 / 11               | 1.26e&#8209;08 |
| 3mm weak meridian (right)                          | 75,410        |         | 29 / 10               | 1.26e&#8209;08 |
| 6mm weak meridian (right)                          | 66,256        |         | 29 / 10               | 2.41e&#8209;08 |
| 3mm weak meridian (left)                           | 75,398        |         | 29 / 10               | 3.96e&#8209;08 |
| 6mm weak meridian (left)                           | 65,551        |         | 29 / 10               | 9.31e&#8209;08 |
| Coronary atherosclerosis                           | 361,194       | 14,334  | 29 / 14               | 3.04e&#8209;06 |
| Ischaemic heart disease (wide definition)          | 361,194       | 20,857  | 29 / 14               | 5.71e&#8209;06 |
| Heart attack                                       | 360,420       | 8,288   | 29 / 14               | 2.36e&#8209;04 |
| Myocardial infarction                              | 361,194       | 7,018   | 29 / 14               | 5.20e&#8209;04 |
| Acute myocardial infarction (ICD10 I21)            | 361,194       | 5,948   | 29 / 14               | 8.14e&#8209;04 |
| heart attack/myocardial infarction (self-reported) | 361,141       | 8,239   | 29 / 14               | 1.16e&#8209;03 |
| Major coronary heart disease event                 | 361,194       | 10,157  | 29 / 14               | 1.47e&#8209;02 |

Table: Significant trait associations of LV136 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv136}
<!-- LV136:phenomexcan_traits_assocs:end -->

<!-- LV136:emerge_traits_assocs:start -->
| Phecode   | Trait description            | Sample size   | Cases   | FDR            |
|:----------|:-----------------------------|:--------------|:--------|:---------------|
| 747.1     | Cardiac congenital anomalies | 59,198        | 1,871   | 1.57e&#8209;01 |
| 411.4     | Coronary atherosclerosis     | 52,836        | 13,715  | 1.60e&#8209;01 |

Table: Trait associations of LV136 in eMERGE. {#tbl:sup:emerge_assocs:lv136}
<!-- LV136:emerge_traits_assocs:end -->


#### LV93

![
**Cell types for LV93.**
<!--  -->
](images/lvs_analysis/lv93/lv93-cell_types.svg "Cell types for LV93"){#fig:sup:lv93 width="80%"}

<!-- LV93:multiplier_pathways:start -->
| Pathway                            | AUC   | FDR   |
|:-----------------------------------|:------|:------|
| No pathways significantly enriched |       |       |

Table: Pathways aligned to LV93 from the MultiPLIER models. {#tbl:sup:multiplier_pathways:lv93}
<!-- LV93:multiplier_pathways:end -->

<!-- LV93:phenomexcan_traits_assocs:start -->
| Trait description                          | Sample size   | Cases   | Partition / cluster   | FDR            |
|:-------------------------------------------|:--------------|:--------|:----------------------|:---------------|
| CH2DB NMR                                  | 24,154        |         | 29 / 16               | 5.91e&#8209;24 |
| Reticulocyte Count                         | 173,480       |         | 29 / 4                | 1.33e&#8209;14 |
| High light scatter reticulocyte count      | 344,729       |         | 29 / 4                | 2.52e&#8209;13 |
| Reticulocyte count                         | 344,729       |         | 29 / 4                | 1.35e&#8209;12 |
| Reticulocyte percentage                    | 344,728       |         | 29 / 4                | 4.93e&#8209;11 |
| High light scatter reticulocyte percentage | 344,729       |         | 29 / 4                | 2.18e&#8209;10 |
| Immature reticulocyte fraction             | 344,728       |         | 29 / 4                | 2.31e&#8209;08 |
| Chronotype                                 | 128,266       |         | 29 / 16               | 9.73e&#8209;04 |
| HDL Cholesterol NMR                        | 19,270        |         | 29 / 16               | 2.41e&#8209;03 |

Table: Significant trait associations of LV93 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv93}
<!-- LV93:phenomexcan_traits_assocs:end -->

<!-- LV93:emerge_traits_assocs:start -->
| Phecode   | Trait description                  | Sample size   | Cases   | FDR            |
|:----------|:-----------------------------------|:--------------|:--------|:---------------|
| 208       | Benign neoplasm of colon           | 55,694        | 8,597   | 1.39e&#8209;02 |
| 440.2     | Atherosclerosis of the extremities | 45,524        | 3,046   | 2.87e&#8209;02 |

Table: Significant trait associations of LV93 in eMERGE. {#tbl:sup:emerge_assocs:lv93}
<!-- LV93:emerge_traits_assocs:end -->


#### LV206

![
**Cell types for LV206.**
<!--  -->
](images/lvs_analysis/lv206/lv206-cell_types.svg "Cell types for LV206"){#fig:sup:lv206 width="80%"}

<!-- LV206:multiplier_pathways:start -->
| Pathway                            | AUC   | FDR   |
|:-----------------------------------|:------|:------|
| No pathways significantly enriched |       |       |

Table: Pathways aligned to LV206 from the MultiPLIER models. {#tbl:sup:multiplier_pathways:lv206}
<!-- LV206:multiplier_pathways:end -->

<!-- LV206:phenomexcan_traits_assocs:start -->
| Trait description   | Sample size   | Cases   | Partition / cluster   | FDR            |
|:--------------------|:--------------|:--------|:----------------------|:---------------|
| CH2DB NMR           | 24,154        |         | 29 / 16               | 5.04e&#8209;21 |
| HDL Cholesterol NMR | 19,270        |         | 29 / 16               | 5.20e&#8209;03 |

Table: Significant trait associations of LV206 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv206}
<!-- LV206:phenomexcan_traits_assocs:end -->

<!-- LV206:emerge_traits_assocs:start -->
| Phecode   | Trait description            | Sample size   | Cases   | FDR            |
|:----------|:-----------------------------|:--------------|:--------|:---------------|
| 458       | Hypotension                  | 51,341        | 4,432   | 3.06e&#8209;02 |
| 286.9     | Abnormal coagulation profile | 48,006        | 800     | 3.39e&#8209;02 |
| 458.9     | Hypotension NOS              | 50,150        | 3,241   | 3.58e&#8209;02 |
| 428.2     | Heart failure NOS            | 48,178        | 3,584   | 3.71e&#8209;02 |

Table: Significant trait associations of LV206 in eMERGE. {#tbl:sup:emerge_assocs:lv206}
<!-- LV206:emerge_traits_assocs:end -->


#### LV260

![
**Cell types for LV260.**
<!--  -->
](images/lvs_analysis/lv260/lv260-cell_types.svg "Cell types for LV260"){#fig:sup:lv260 width="80%"}

<!-- LV260:multiplier_pathways:start -->
| Pathway                            | AUC   | FDR   |
|:-----------------------------------|:------|:------|
| No pathways significantly enriched |       |       |

Table: Pathways aligned to LV260 from the MultiPLIER models. {#tbl:sup:multiplier_pathways:lv260}
<!-- LV260:multiplier_pathways:end -->

<!-- LV260:phenomexcan_traits_assocs:start -->
| Trait description   | Sample size   | Cases   | Partition / cluster   | FDR            |
|:--------------------|:--------------|:--------|:----------------------|:---------------|
| CH2DB NMR           | 24,154        |         | 29 / 16               | 4.35e&#8209;17 |
| HDL Cholesterol NMR | 19,270        |         | 29 / 16               | 1.88e&#8209;02 |

Table: Significant trait associations of LV260 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv260}
<!-- LV260:phenomexcan_traits_assocs:end -->

<!-- LV260:emerge_traits_assocs:start -->
| Phecode   | Trait description   | Sample size   | Cases   | FDR            |
|:----------|:--------------------|:--------------|:--------|:---------------|
| 427.6     | Premature beats     | 31,575        | 2,453   | 7.90e&#8209;02 |

Table: Trait associations of LV260 in eMERGE. {#tbl:sup:emerge_assocs:lv260}
<!-- LV260:emerge_traits_assocs:end -->


#### LV21

![
**Cell types for LV21.**
<!--  -->
](images/lvs_analysis/lv21/lv21-cell_types.svg "Cell types for LV21"){#fig:sup:lv21 width="80%"}

<!-- LV21:multiplier_pathways:start -->
| Pathway                            | AUC   | FDR   |
|:-----------------------------------|:------|:------|
| No pathways significantly enriched |       |       |

Table: Pathways aligned to LV21 from the MultiPLIER models. {#tbl:sup:multiplier_pathways:lv21}
<!-- LV21:multiplier_pathways:end -->

<!-- LV21:phenomexcan_traits_assocs:start -->
| Trait description   | Sample size   | Cases   | Partition / cluster   | FDR            |
|:--------------------|:--------------|:--------|:----------------------|:---------------|
| Alzheimers Disease  | 54,162        | 17,008  | 29 / 16               | 1.11e&#8209;19 |
| LDL Cholesterol NMR | 13,527        |         | 29 / 16               | 9.53e&#8209;05 |
| Triglycerides NMR   | 21,559        |         | 29 / 16               | 1.74e&#8209;02 |

Table: Significant trait associations of LV21 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv21}
<!-- LV21:phenomexcan_traits_assocs:end -->

<!-- LV21:emerge_traits_assocs:start -->
| Phecode   | Trait description        | Sample size   | Cases   | FDR            |
|:----------|:-------------------------|:--------------|:--------|:---------------|
| 573       | Other disorders of liver | 47,826        | 2,524   | 2.99e&#8209;02 |
| 577       | Diseases of pancreas     | 60,538        | 1,795   | 5.51e&#8209;02 |

Table: Trait associations of LV21 in eMERGE. {#tbl:sup:emerge_assocs:lv21}
<!-- LV21:emerge_traits_assocs:end -->


#### LV5

![
**Cell types for LV5.**
<!--  -->
](images/lvs_analysis/lv5/lv5-cell_types.svg "Cell types for LV5"){#fig:sup:lv5 width="80%"}

<!-- LV5:multiplier_pathways:start -->
| Pathway                            | AUC   | FDR   |
|:-----------------------------------|:------|:------|
| No pathways significantly enriched |       |       |

Table: Pathways aligned to LV5 from the MultiPLIER models. {#tbl:sup:multiplier_pathways:lv5}
<!-- LV5:multiplier_pathways:end -->

<!-- LV5:phenomexcan_traits_assocs:start -->
| Trait description                                             | Sample size   | Cases   | Partition / cluster   | FDR            |
|:--------------------------------------------------------------|:--------------|:--------|:----------------------|:---------------|
| LDL Cholesterol NMR                                           | 13,527        |         | 29 / 16               | 1.44e&#8209;04 |
| Triglycerides NMR                                             | 21,559        |         | 29 / 16               | 4.03e&#8209;04 |
| Alzheimers Disease                                            | 54,162        | 17,008  | 29 / 16               | 2.47e&#8209;03 |
| Ever had prolonged feelings of sadness or depression          | 117,763       | 64,374  | 29 / 27               | 6.92e&#8209;03 |
| Medication for depression                                     | 117,763       | 28,351  | 29 / 27               | 8.24e&#8209;03 |
| Recent feelings of depression                                 | 117,656       |         | 29 / 27               | 1.05e&#8209;02 |
| Ever contemplated self-harm                                   | 117,610       |         | 29 / 27               | 1.50e&#8209;02 |
| Recent lack of interest or pleasure in doing things           | 117,757       |         | 29 / 27               | 1.65e&#8209;02 |
| Amount of alcohol drunk on a typical drinking day             | 108,256       |         | 29 / 27               | 2.77e&#8209;02 |
| Ever sought or received professional help for mental distress | 117,677       | 46,020  | 29 / 27               | 3.08e&#8209;02 |
| General happiness                                             | 117,442       |         | 29 / 27               | 3.73e&#8209;02 |
| Depression (diagnosed by a professional)                      | 117,782       | 25,087  | 29 / 27               | 4.03e&#8209;02 |

Table: Significant trait associations of LV5 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv5}
<!-- LV5:phenomexcan_traits_assocs:end -->

<!-- LV5:emerge_traits_assocs:start -->
| Phecode   | Trait description          | Sample size   | Cases   | FDR            |
|:----------|:---------------------------|:--------------|:--------|:---------------|
| 241       | Nontoxic nodular goiter    | 47,842        | 3,158   | 1.92e&#8209;02 |
| 241.1     | Nontoxic uninodular goiter | 47,125        | 2,441   | 6.84e&#8209;02 |

Table: Trait associations of LV5 in eMERGE. {#tbl:sup:emerge_assocs:lv5}
<!-- LV5:emerge_traits_assocs:end -->


#### LV434

![
**Cell types for LV434.**
HEK293 is a cell line derived from human embryonic kidney cells;
3T3 is a cell line derived from mouse embryonic fibroblasts.
](images/lvs_analysis/lv434/lv434-cell_types.svg "Cell types for LV434"){#fig:sup:lv434 width="80%"}

<!-- LV434:multiplier_pathways:start -->
| Pathway                            | AUC   | FDR   |
|:-----------------------------------|:------|:------|
| No pathways significantly enriched |       |       |

Table: Pathways aligned to LV434 from the MultiPLIER models. {#tbl:sup:multiplier_pathways:lv434}
<!-- LV434:multiplier_pathways:end -->

<!-- LV434:phenomexcan_traits_assocs:start -->
| Trait description                        | Sample size   | Cases   | Partition / cluster   | FDR            |
|:-----------------------------------------|:--------------|:--------|:----------------------|:---------------|
| Attention Deficit Hyperactivity Disorder | 53,293        | 19,099  | 29 / 21               | 5.62e&#8209;03 |

Table: Significant trait associations of LV434 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv434}
<!-- LV434:phenomexcan_traits_assocs:end -->

<!-- LV434:emerge_traits_assocs:start -->
| Phecode   | Trait description                | Sample size   | Cases   | FDR            |
|:----------|:---------------------------------|:--------------|:--------|:---------------|
| 722       | Intervertebral disc disorders    | 47,659        | 7,458   | 1.44e&#8209;02 |
| 721       | Spondylosis and allied disorders | 47,517        | 7,316   | 1.64e&#8209;02 |
| 250.4     | Abnormal glucose                 | 45,220        | 4,947   | 2.23e&#8209;02 |
| 721.1     | Spondylosis without myelopathy   | 47,315        | 7,114   | 2.66e&#8209;02 |
| 720       | Spinal stenosis                  | 44,807        | 4,606   | 3.99e&#8209;02 |

Table: Significant trait associations of LV434 in eMERGE. {#tbl:sup:emerge_assocs:lv434}
<!-- LV434:emerge_traits_assocs:end -->
